Investment
Features
FeesSafety
Academy
More
Pluang+

Compare NetFlix Inc (NFLX) vs Novo Nordisk A/S (NVO) Price & Performance

NetFlix IncTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

NetFlix Inc vs Novo Nordisk A/S — how do they compare? NetFlix Inc trades at $75.35 (market cap $311.42B), while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: NetFlix Inc is the larger of the two by market cap, and Novo Nordisk A/S pays a 3.81% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals.

NFLXNVO
Market Cap
$311.42B$207.85B
Sector
Consumer CyclicalHealth
52-Week High
$126.33$63.98
52-Week Low
$67.60$35.29
Enterprise Value
$316.60B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

NetFlix Inc

Netflix (NFLX) trades at $76.29, up 2.9% in the last session, showing resilience amid recent volatility. The stock exhibits bullish technical signals with strong moving average alignment, though RSI levels suggest potential overbought conditions near-term. Fundamentally, Netflix demonstrates robust growth with Q1 2026 EPS beating expectations at $1.23 versus $0.763, and revenue climbing to $45.18 billion in 2025. Operating cash flow surged to $10.15 billion, underscoring financial health. The company's expansion into advertising and live sports is viewed positively by analysts.

Outlook remains favorable with a consensus price target of $90.45, implying ~19% upside, supported by 64% analyst buy ratings. Key opportunities include ad-tier monetization and global content leadership. Risks involve competitive pressures from streaming rivals, execution on new initiatives, and market sentiment shifts. The stock's current valuation at P/E 23.52 appears reasonable given earnings growth trajectory, but investors should monitor quarterly execution against high expectations.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About NetFlix Inc

Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.

Read more on NFLX

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO